SG11202103796TA - Indole ahr inhibitors and uses thereof - Google Patents
Indole ahr inhibitors and uses thereofInfo
- Publication number
- SG11202103796TA SG11202103796TA SG11202103796TA SG11202103796TA SG11202103796TA SG 11202103796T A SG11202103796T A SG 11202103796TA SG 11202103796T A SG11202103796T A SG 11202103796TA SG 11202103796T A SG11202103796T A SG 11202103796TA SG 11202103796T A SG11202103796T A SG 11202103796TA
- Authority
- SG
- Singapore
- Prior art keywords
- ahr inhibitors
- indole
- indole ahr
- inhibitors
- ahr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862746277P | 2018-10-16 | 2018-10-16 | |
| PCT/US2019/056455 WO2020081636A1 (en) | 2018-10-16 | 2019-10-16 | Indole ahr inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202103796TA true SG11202103796TA (en) | 2021-05-28 |
Family
ID=70284697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202103796TA SG11202103796TA (en) | 2018-10-16 | 2019-10-16 | Indole ahr inhibitors and uses thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220144839A1 (es) |
| EP (1) | EP3867253A4 (es) |
| JP (1) | JP2022502476A (es) |
| KR (1) | KR20210110566A (es) |
| CN (1) | CN113272305A (es) |
| AU (1) | AU2019360204A1 (es) |
| BR (1) | BR112021007017A2 (es) |
| CA (1) | CA3115711A1 (es) |
| EA (1) | EA202190726A1 (es) |
| IL (1) | IL282252A (es) |
| MX (1) | MX2021004245A (es) |
| SG (1) | SG11202103796TA (es) |
| WO (1) | WO2020081636A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023502531A (ja) | 2019-11-26 | 2023-01-24 | イケナ オンコロジー， インコーポレイテッド | 多形カルバゾール誘導体およびその使用 |
| JP2023510797A (ja) | 2020-01-10 | 2023-03-15 | イケナ オンコロジー， インコーポレイテッド | Ａｈｒ阻害剤及びその使用 |
| WO2022078356A1 (zh) * | 2020-10-15 | 2022-04-21 | 山东轩竹医药科技有限公司 | 杂芳环类AhR抑制剂 |
| EP4236960A1 (en) * | 2020-10-28 | 2023-09-06 | Ikena Oncology, Inc. | Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine |
| IL302990A (en) | 2020-11-23 | 2023-07-01 | Enanta Pharm Inc | Antivirals that are derivatives of the novel spiropyrrolidine |
| CN114456178B (zh) * | 2021-01-13 | 2023-06-02 | 北京华森英诺生物科技有限公司 | 四氢嘧啶[1,2-b]吲唑-4-胺类衍生物作为AhR抑制剂的用途及制备方法 |
| CN114805361B (zh) * | 2021-01-17 | 2024-02-20 | 上海凌达生物医药有限公司 | 一类氨基取代的芳香杂环并吡唑类化合物、制备方法和用途 |
| WO2022235605A1 (en) | 2021-05-04 | 2022-11-10 | Enanta Pharmaceuticals, Inc. | Novel macrocyclic antiviral agents |
| WO2023086400A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| US11858945B2 (en) | 2021-11-12 | 2024-01-02 | Enanta Pharmaceuticals, Inc. | Alkyne-containing antiviral agents |
| US11912714B2 (en) | 2021-11-12 | 2024-02-27 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US20230234922A1 (en) * | 2022-01-11 | 2023-07-27 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of 4,6,7-trifluoro-1h-indole-2-carboxylic acid |
| CN117624168A (zh) * | 2022-08-19 | 2024-03-01 | 德明药泰生物技术（深圳）有限公司 | 稠环杂环类化合物及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5721356A (en) * | 1989-09-15 | 1998-02-24 | Gensia, Inc. | Orally active adenosine kinase inhibitors |
| AU2004230928B2 (en) * | 2003-04-09 | 2010-12-02 | Exelixis, Inc. | Tie-2 modulators and methods of use |
| AR047969A1 (es) * | 2004-02-25 | 2006-03-15 | Schering Corp | Pirazolotriazinas como inhibidores de quinasa |
| PE20100362A1 (es) * | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| US10167270B2 (en) * | 2015-07-01 | 2019-01-01 | Northwestern University | Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity |
| US20180072741A1 (en) * | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
| CA3059939A1 (en) * | 2017-04-21 | 2018-10-25 | Kyn Therapeutics | Indole ahr inhibitors and uses thereof |
-
2019
- 2019-10-16 KR KR1020217014753A patent/KR20210110566A/ko not_active Application Discontinuation
- 2019-10-16 CA CA3115711A patent/CA3115711A1/en active Pending
- 2019-10-16 US US17/281,395 patent/US20220144839A1/en active Pending
- 2019-10-16 AU AU2019360204A patent/AU2019360204A1/en active Pending
- 2019-10-16 MX MX2021004245A patent/MX2021004245A/es unknown
- 2019-10-16 WO PCT/US2019/056455 patent/WO2020081636A1/en unknown
- 2019-10-16 CN CN201980076086.7A patent/CN113272305A/zh active Pending
- 2019-10-16 BR BR112021007017-6A patent/BR112021007017A2/pt unknown
- 2019-10-16 EA EA202190726A patent/EA202190726A1/ru unknown
- 2019-10-16 SG SG11202103796TA patent/SG11202103796TA/en unknown
- 2019-10-16 EP EP19873025.1A patent/EP3867253A4/en active Pending
- 2019-10-16 JP JP2021521024A patent/JP2022502476A/ja active Pending
-
2021
- 2021-04-12 IL IL282252A patent/IL282252A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220144839A1 (en) | 2022-05-12 |
| IL282252A (en) | 2021-05-31 |
| BR112021007017A2 (pt) | 2021-07-13 |
| CN113272305A (zh) | 2021-08-17 |
| WO2020081636A1 (en) | 2020-04-23 |
| MX2021004245A (es) | 2021-09-08 |
| JP2022502476A (ja) | 2022-01-11 |
| EA202190726A1 (ru) | 2021-08-19 |
| EP3867253A1 (en) | 2021-08-25 |
| CA3115711A1 (en) | 2020-04-23 |
| EP3867253A4 (en) | 2022-05-18 |
| AU2019360204A1 (en) | 2021-06-03 |
| KR20210110566A (ko) | 2021-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282252A (en) | Indole AHR inhibitors and their uses | |
| EP3612030A4 (en) | AHR INDOLE INHIBITORS AND THEIR USES | |
| IL282487A (en) | TYK2 inhibitors and their use | |
| IL283639A (en) | kif18a inhibitors | |
| IL271999A (en) | TYK2 inhibitors and uses thereof | |
| IL270490B (en) | kras g12c inhibitors and methods of using them | |
| IL276095B1 (en) | gcn2 inhibitors and their uses | |
| IL276147A (en) | GCN2 inhibitors and uses thereof | |
| IL272649A (en) | AHR inhibitors and their uses | |
| IL282090A (en) | tyk2 inhibitors and uses thereof | |
| IL274710A (en) | Indole compounds and their use | |
| IL283409A (en) | tyk2 inhibitors and uses thereof | |
| IL270330B (en) | Beta-lactamase inhibitors and their uses | |
| IL268619B (en) | Piperidine-converted mnk inhibitors and related methods | |
| IL280051A (en) | EP4 inhibitors and their synthesis | |
| LT3621694T (lt) | Lrrc33 inhibitoriai ir jų panaudojimas | |
| IL282350A (en) | Bernani-RGMC inhibitors and their use | |
| IL281769A (en) | CD40L antagonist and uses thereof | |
| IL276013A (en) | pi4kiiibeta inhibitors | |
| IL286622A (en) | prmt5 inhibitors and uses thereof | |
| IL286485A (en) | pi4-kinase inhibitors and methods of using them | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | |
| IL280408A (en) | CDK inhibitors and uses thereof | |
| HK1251875A1 (zh) | 作為crth2抑制劑的吲哚類化合物 | |
| GB201908884D0 (en) | Inhibitors and use |